• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Taurinated bile acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Bile acids, alcohols and derivatives Taurinated bile acids and derivatives

Taurodeoxycholic-d4 Acid (CAS No. 1332881-65-8): An Overview of a Promising Compound in Biomedical Research

Taurodeoxycholic-d4 Acid (CAS No. 1332881-65-8) is a deuterated derivative of taurodeoxycholic acid, a bile acid that plays a crucial role in various physiological processes. This compound has gained significant attention in recent years due to its potential applications in biomedical research, particularly in the fields of drug metabolism, pharmacokinetics, and disease biomarker studies.

The primary function of taurodeoxycholic acid is to facilitate the absorption of fats and fat-soluble vitamins in the intestines. It is synthesized from cholesterol in the liver and conjugated with taurine to form taurodeoxycholic acid. The deuterated form, Taurodeoxycholic-d4 Acid, is structurally identical to its non-deuterated counterpart but contains four deuterium atoms, which can significantly alter its metabolic stability and pharmacokinetic properties.

Recent studies have highlighted the importance of bile acids, including taurodeoxycholic acid, in regulating various metabolic pathways. For instance, bile acids are known to activate nuclear receptors such as farnesoid X receptor (FXR) and G protein-coupled bile acid receptor (TGR5), which are involved in glucose and lipid metabolism. The deuterated form, Taurodeoxycholic-d4 Acid, has been used as a stable isotope tracer to investigate these pathways more accurately.

In the context of drug metabolism, Taurodeoxycholic-d4 Acid serves as an excellent tool for studying the biotransformation of bile acids and their interactions with drug-metabolizing enzymes. Deuterium labeling can provide valuable insights into the metabolic fate of these compounds, helping researchers understand how they are processed by the liver and other organs. This information is crucial for optimizing drug formulations and predicting potential drug-drug interactions.

Beyond its role in metabolism, Taurodeoxycholic-d4 Acid has also shown promise in disease biomarker research. Bile acids are known to be dysregulated in various diseases, including liver diseases, metabolic disorders, and certain types of cancer. By using deuterated bile acids as tracers, researchers can more accurately measure changes in bile acid levels and identify potential biomarkers for early diagnosis and prognosis.

Clinical trials involving Taurodeoxycholic-d4 Acid have demonstrated its utility in assessing the efficacy of therapeutic interventions. For example, in patients with non-alcoholic fatty liver disease (NAFLD), the administration of deuterated bile acids can help monitor changes in bile acid homeostasis and evaluate the effectiveness of treatments aimed at restoring normal metabolic function.

The use of deuterated compounds like Taurodeoxycholic-d4 Acid also has implications for personalized medicine. By providing detailed information on individual metabolic profiles, these tracers can help tailor treatment strategies to specific patient needs, potentially improving outcomes and reducing side effects.

In conclusion, Taurodeoxycholic-d4 Acid (CAS No. 1332881-65-8) is a valuable tool in biomedical research, offering unique insights into bile acid metabolism, drug interactions, and disease biomarkers. Its stable isotope properties make it an ideal tracer for a wide range of applications, from basic research to clinical diagnostics. As our understanding of bile acid biology continues to evolve, the role of compounds like Taurodeoxycholic-d4 Acid will likely become even more significant in advancing medical science.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)